Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. / Kari, Vijayalakshmi; Mansour, Wael Yassin; Raul, Sanjay Kumar; Baumgart, Simon J; Mund, Andreas; Grade, Marian; Sirma, Hüseyin; Simon, Ronald; Will, Hans; Dobbelstein, Matthias; Dikomey, Ekkehard; Johnsen, Steven A.

In: E M B O Reports, Vol. 17, No. 11, 01.11.2016, p. 1609-1623.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kari, V, Mansour, WY, Raul, SK, Baumgart, SJ, Mund, A, Grade, M, Sirma, H, Simon, R, Will, H, Dobbelstein, M, Dikomey, E & Johnsen, SA 2016, 'Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness', E M B O Reports, vol. 17, no. 11, pp. 1609-1623. https://doi.org/10.15252/embr.201642352

APA

Kari, V., Mansour, W. Y., Raul, S. K., Baumgart, S. J., Mund, A., Grade, M., Sirma, H., Simon, R., Will, H., Dobbelstein, M., Dikomey, E., & Johnsen, S. A. (2016). Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. E M B O Reports, 17(11), 1609-1623. https://doi.org/10.15252/embr.201642352

Vancouver

Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M et al. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. E M B O Reports. 2016 Nov 1;17(11):1609-1623. https://doi.org/10.15252/embr.201642352

Author

Kari, Vijayalakshmi ; Mansour, Wael Yassin ; Raul, Sanjay Kumar ; Baumgart, Simon J ; Mund, Andreas ; Grade, Marian ; Sirma, Hüseyin ; Simon, Ronald ; Will, Hans ; Dobbelstein, Matthias ; Dikomey, Ekkehard ; Johnsen, Steven A. / Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. In: E M B O Reports. 2016 ; Vol. 17, No. 11. pp. 1609-1623.

Bibtex

@article{6464bee47703491ca65724a2cd68f533,
title = "Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness",
abstract = "The CHD1 gene, encoding the chromo-domain helicase DNA-binding protein-1, is one of the most frequently deleted genes in prostate cancer. Here, we examined the role of CHD1 in DNA double-strand break (DSB) repair in prostate cancer cells. We show that CHD1 is required for the recruitment of CtIP to chromatin and subsequent end resection during DNA DSB repair. Our data support a role for CHD1 in opening the chromatin around the DSB to facilitate the recruitment of homologous recombination (HR) proteins. Consequently, depletion of CHD1 specifically affects HR-mediated DNA repair but not non-homologous end joining. Together, we provide evidence for a previously unknown role of CHD1 in DNA DSB repair via HR and show that CHD1 depletion sensitizes cells to PARP inhibitors, which has potential therapeutic relevance. Our findings suggest that CHD1 deletion, like BRCA1/2 mutation in ovarian cancer, may serve as a marker for prostate cancer patient stratification and the utilization of targeted therapies such as PARP inhibitors, which specifically target tumors with HR defects.",
author = "Vijayalakshmi Kari and Mansour, {Wael Yassin} and Raul, {Sanjay Kumar} and Baumgart, {Simon J} and Andreas Mund and Marian Grade and H{\"u}seyin Sirma and Ronald Simon and Hans Will and Matthias Dobbelstein and Ekkehard Dikomey and Johnsen, {Steven A}",
note = "{\textcopyright} 2016 The Authors.",
year = "2016",
month = nov,
day = "1",
doi = "10.15252/embr.201642352",
language = "English",
volume = "17",
pages = "1609--1623",
journal = "E M B O Reports",
issn = "1469-221X",
publisher = "Wiley-Blackwell",
number = "11",

}

RIS

TY - JOUR

T1 - Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness

AU - Kari, Vijayalakshmi

AU - Mansour, Wael Yassin

AU - Raul, Sanjay Kumar

AU - Baumgart, Simon J

AU - Mund, Andreas

AU - Grade, Marian

AU - Sirma, Hüseyin

AU - Simon, Ronald

AU - Will, Hans

AU - Dobbelstein, Matthias

AU - Dikomey, Ekkehard

AU - Johnsen, Steven A

N1 - © 2016 The Authors.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The CHD1 gene, encoding the chromo-domain helicase DNA-binding protein-1, is one of the most frequently deleted genes in prostate cancer. Here, we examined the role of CHD1 in DNA double-strand break (DSB) repair in prostate cancer cells. We show that CHD1 is required for the recruitment of CtIP to chromatin and subsequent end resection during DNA DSB repair. Our data support a role for CHD1 in opening the chromatin around the DSB to facilitate the recruitment of homologous recombination (HR) proteins. Consequently, depletion of CHD1 specifically affects HR-mediated DNA repair but not non-homologous end joining. Together, we provide evidence for a previously unknown role of CHD1 in DNA DSB repair via HR and show that CHD1 depletion sensitizes cells to PARP inhibitors, which has potential therapeutic relevance. Our findings suggest that CHD1 deletion, like BRCA1/2 mutation in ovarian cancer, may serve as a marker for prostate cancer patient stratification and the utilization of targeted therapies such as PARP inhibitors, which specifically target tumors with HR defects.

AB - The CHD1 gene, encoding the chromo-domain helicase DNA-binding protein-1, is one of the most frequently deleted genes in prostate cancer. Here, we examined the role of CHD1 in DNA double-strand break (DSB) repair in prostate cancer cells. We show that CHD1 is required for the recruitment of CtIP to chromatin and subsequent end resection during DNA DSB repair. Our data support a role for CHD1 in opening the chromatin around the DSB to facilitate the recruitment of homologous recombination (HR) proteins. Consequently, depletion of CHD1 specifically affects HR-mediated DNA repair but not non-homologous end joining. Together, we provide evidence for a previously unknown role of CHD1 in DNA DSB repair via HR and show that CHD1 depletion sensitizes cells to PARP inhibitors, which has potential therapeutic relevance. Our findings suggest that CHD1 deletion, like BRCA1/2 mutation in ovarian cancer, may serve as a marker for prostate cancer patient stratification and the utilization of targeted therapies such as PARP inhibitors, which specifically target tumors with HR defects.

U2 - 10.15252/embr.201642352

DO - 10.15252/embr.201642352

M3 - Journal article

C2 - 27596623

VL - 17

SP - 1609

EP - 1623

JO - E M B O Reports

JF - E M B O Reports

SN - 1469-221X

IS - 11

ER -

ID: 166505925